Literature DB >> 22778380

Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis.

João Bento1, Raquel Duarte, Maria Céu Brito, Sónia Leite, Maria Rosário Lobato, Maria do Carmo Caldeira, Aurora Carvalho.   

Abstract

Malabsorption of oral antimycobacterial drugs is a rare cause of treatment failure in tuberculosis (TB). Several predisposing comorbidities have been recognised. HIV infection is the most important risk factor referred in the literature. There are few reports about antimycobacterial drugs malabsorption, particularly in the absence of predisposing comorbidities. The authors present a clinical case of oral treatment failure in TB due to malabsorption; however, what caused the failure remained unclear. Possible causes of malabsorption are discussed under various sections. Purpose of this case report is to point to this rare situation that can easily go unnoticed unless a very high level of suspicion is present.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22778380      PMCID: PMC3028077          DOI: 10.1136/bcr.12.2009.2554

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.

Authors:  Valéria G F Pinheiro; Lysiane M A Ramos; Helena S A Monteiro; Elizabeth C Barroso; Oluma Y Bushen; Mônica C Façanha; Charles A Peloquin; Richard L Guerrant; Aldo A M Lima
Journal:  Braz J Infect Dis       Date:  2006-12       Impact factor: 1.949

2.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy.

Authors:  J B Mehta; H Shantaveerapa; R P Byrd; S E Morton; F Fountain; T M Roy
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

3.  Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.

Authors:  M E Kimerling; P Phillips; P Patterson; M Hall; C A Robinson; N E Dunlap
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

4.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Drug malabsorption and resistant tuberculosis in HIV-infected patients.

Authors:  K B Patel; R Belmonte; H M Crowe
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

6.  Malabsorption of antimycobacterial medications.

Authors:  C A Peloquin; A A MacPhee; S E Berning
Journal:  N Engl J Med       Date:  1993-10-07       Impact factor: 91.245

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.

Authors:  Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; S Bhagavathy; P Venkatesan; L Sekar; A Mahilmaran; N Ravichandran; P Paramesh
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

9.  Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.

Authors:  J Sahai; K Gallicano; L Swick; S Tailor; G Garber; I Seguin; L Oliveras; S Walker; A Rachlis; D W Cameron
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

  9 in total
  1 in total

1.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.